PharmTech Drug Digest 11.20
News|Articles|May 15, 2013

Report Previews Future of U.S. Biosimilar Market

Thomson Reuters released a report that provides a view of the challenges facing companies entering the United States biosimilar drug market.

The IP & Science business of Thomson Reuters released a life sciences report, “An Outlook on U.S. Biosimilar Competition,” which provides a view of the challenges facing companies entering the United States biosimilar drug market and key players predicted to break into this developing pharmaceutical space.

While the US continues to take steps toward entering the global biosimilar market, it lags behind other nations in this space, the report says. The report compares US and EU regulations to underscore the significant differences between these regions and explore ways the US can compete more effectively, in addition to reviewing emerging regulatory developments in India and China. It also identifies potential leaders of the US market, including Amgen, Hospira, and Sandoz, among the top pharmaceutical companies with the most potential to dominate the early stages of biosimilar medications entering the US.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.